Information updates

ASCIA website updates: Chlorhexidine allergy (new) and Anaphylaxis guidelines (updated)

November 28, 2017

The following 2 ASCIA documents are now available on the ASCIA website - new ASCIA-ANZAAG Chlorhexidine allergy information and updated ASCIA Guidelines for acute management of anaphylaxis for health professionals.

New ASCIA-ANZAAG Chlorhexidine (antiseptic agent) allergy information for patients, consumers and carers, was developed in conjunction with ANZAAG, the Australian and New Zealand Anaesthetic Allergy Group, and is available at    

Chlorhexidine is a highly effective antiseptic agent. Whilst allergic reactions to chlorhexidine are rare, they are increasing in frequency, which is possibly related to increased use of chlorhexidine containing products in recent years. Chlorhexidine is used in a large number of products and its presence can sometimes be ‘hidden’. As antibiotic resistant organisms are becoming more common, its use in both prevention and treatment of infection is likely to continue.

Updated ASCIA Guidelines for acute management of anaphylaxis (for health professionals) are available at  These updated guidelines include:

  • Advanced acute management information as an Appendix, which was previously in a separate document. 
  • Information about emergency treatment for anaphylaxis in patients with known asthma and severe allergies on page 1. This is the same information that has been on the ASCIA Action Plans for Anaphylaxis since 2016.
  • Infographics that reinforce correct positioning of patients on page 1. These are the same infographics that have been on the ASCIA Action Plans for Anaphylaxis since 2016.  Detailed information regarding  positioning of patients is on page 2.
  • Simplified adrenaline infusion and dose guidelines on page 2, under a new heading, “Adrenaline administration and dosages”.
  • Advice on discharge procedures on page 4, under the revised heading, “Follow up treatment including advice for hospital discharge”.

Significant amendments have also recently been made to the ASCIA website so that now there is one quick-link on the ASCIA website homepage  to access all ASCIA anaphylaxis resources, including these updated guidelines. This has already greatly improved online search results, accessibility of ASCIA anaphylaxis resources and reduced the number of ‘clicks’ required to obtain relevant information. 

Mod ASCIA Member
Donate to AIFA
go to NAS website
ASCIA Member Login
ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.
See latest edition here...
Join our mailing list:


ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links


ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.



This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.